Diagnostic Firm diaDexus Awaits Possible Boom From GlaxoSmithKline (GSK) Trials
10/24/2013 8:21:52 AM
Medical researchers often find tantalizing hints about the causes of disease when they spot biomolecules that seem to be closely associated with the onset of an illness—like the amyloid plaques seen in the brains of people with Alzheimer’s disease. Pharmaceutical companies often run with those hints, creating experimental drugs targeted at those suspect biomolecules. But are the suspect disease markers actually causing the illness, or are they just incidental symptoms or byproducts of it? Will a drug targeting a disease marker do anything to combat the disease?
Hey, check out all the engineering jobs. Post your resume today!
comments powered by